Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 8/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | HRH1 | P35367 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 4/20 | 0.45 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.44 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.44 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3996051 | 0.98 | CA2 (0.56) | CA2MAPK1CHRM1AKR1A1CHRM3 | |
| SCHEMBL28453202 | 0.96 | CA2 (0.54) | CA2MAPK1CHRM1AKR1A1CHRM3 | |
| SCHEMBL28312932 | 0.93 | GPR84 (0.54) | CA2MAPK1CHRM1AKR1A1CHRM3 | |
| SCHEMBL152526 | 0.93 | CA2 (0.58) | CA2MAPK1CHRM1AKR1A1CHRM3 | |
| SCHEMBL8816556 | 0.91 | GPR84 (0.57) | CA2MAPK1GPR84FFAR1MAPT | |
| SCHEMBL11390310 | 0.91 | GPR84 (0.57) | CA2MAPK1GPR84FFAR1MAPT | |
| SCHEMBL27878051 | 0.91 | GPR84 (0.57) | CA2MAPK1GPR84FFAR1MAPT | |
| SCHEMBL337541 | 0.91 | GPR84 (0.57) | CA2MAPK1GPR84FFAR1MAPT | |
| SCHEMBL7295527 | 0.91 | GPR84 (0.57) | CA2MAPK1GPR84FFAR1MAPT | |
| SCHEMBL28159626 | 0.90 | TDP1 (0.46) | CA2MAPK1CHRM1AKR1A1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4065113-B1 | (R)-4-(1-(6-(4-(TRIFLUOROMETHYL)BENZYL)-6-AZASPIRO[2.5]OCTANE-5-CARBOXAMIDO)-CYCLOPROPYL) BENZOIC ACID OR ITS SALT ALSO IN POLYMORPHIC FORM A FOR USE IN THE PREVENTION OF HETEROTOPIC OSSIFICATION | Rottapharm Biotech Srl (IT) | 2024-01-10 | — | — | EP | disclosed |
| US-11590114-B2 | Pharmaceutical combination of an EP4 antagonist and immune checkpoint inhibitors for the treatment of tumours | ROTTAPHARM BIOTECH S.R.L. (IT) | 2023-02-28 | — | — | US | disclosed |
| EP-3953393-B1 | PHARMACEUTICAL COMBINATION OF AN EP4 ANTAGONIST AND IMMUNE CHECKPOINT INHIBITORS FOR THE TREATMENT OF TUMOURS | Rottapharm Biotech Srl (IT) | 2022-12-14 | — | — | EP | disclosed |
| CN-109661398-B | Spiro-lactam and di-spiro-lactam NMDA receptor modulators and uses thereof | 阿普廷伊克斯股份有限公司 | 2022-07-05 | — | — | CN | disclosed |
| US-20220142996-A1 | PHARMACEUTICAL COMBINATION OF AN EP4 ANTAGONIST AND IMMUNE CHECKPOINT INHIBITORS FOR THE TREATMENT OF TUMOURS | ROTTAPHARM BIOTECH S.R.L. (IT) | 2022-05-12 | — | — | US | disclosed |
| EP-3953393-A1 | PHARMACEUTICAL COMBINATION OF AN EP4 ANTAGONIST AND IMMUNE CHECKPOINT INHIBITORS FOR THE TREATMENT OF TUMOURS | Rottapharm Biotech S.r.l. (IT) | 2022-02-16 | — | — | EP | disclosed |
| WO-2021105419-A1 | (R)-4-(1-(6-(4-(TRIFLUOROMETHYL)BENZYL)-6-AZASPIRO[2.5]OCTANE-5-CARBOXAMIDO)-CYCLOPROPYL) BENZOIC ACID OR ITS SALT ALSO IN POLYMORPHIC FORM A FOR USE IN THE PREVENTION OF HETEROTOPIC OSSIFICATION | ROTTAPHARM BIOTECH S.R.L. (IT) | 2021-06-03 | — | — | WO | disclosed |
| EP-3827828-A1 | (R)-4-(1-(6-(4-(TRIFLUOROMETHYL)BENZYL)-6-AZASPIRO[2.5]OCTANE-5-CARBOXAMIDO)-CYCLOPROPYL) BENZOIC ACID OR ITS SALT ALSO IN POLYMORPHIC FORM A FOR USE IN THE PREVENTION OF HETEROTOPIC OSSIFICATION | Rottapharm Biotech S.r.l. (IT) | 2021-06-02 | — | — | EP | disclosed |
| WO-2020208088-A1 | PHARMACEUTICAL COMBINATION OF AN EP4 ANTAGONIST AND IMMUNE CHECKPOINT INHIBITORS FOR THE TREATMENT OF TUMOURS | ROTTAPHARM BIOTECH S.R.L. (IT) | 2020-10-15 | — | — | WO | disclosed |
| CN-106608841-B | The preparation method of 2- cyano -2,3- dialkyl succinic acid dialkyl ester class compounds | 中国石油化工股份有限公司 | 2018-06-12 | — | — | CN | disclosed |
| EP-1607448-A2 | Surface modified silica gels | Degussa AG (DE) | 2005-12-21 | — | — | EP | disclosed |
| EP-0971981-B1 | EMULSIFIERS FOR AMINO RESINS | BASF AG (DE) | 2004-10-13 | — | — | EP | disclosed |
| EP-0971973-B1 | SOLUTIONS OF AMINOTRIAZINE RESINS IN MONOALKYLGLYCOLS | BASF AG (DE) | 2001-10-24 | — | — | EP | disclosed |
| EP-0971981-A1 | EMULSIFIERS FOR AMINO RESINS | BASF AKTIENGESELLSCHAFT (DE) | 2000-01-19 | — | — | EP | disclosed |
| EP-0971973-A1 | SOLUTIONS OF AMINOTRIAZINE RESINS IN MONOALKYLGLYCOLS | BASF AKTIENGESELLSCHAFT (DE) | 2000-01-19 | — | — | EP | disclosed |
| WO-1998045370-A1 | EMULSIFIERS FOR AMINO RESINS | BASF AKTIENGESELLSCHAFT (DE) | 1998-10-15 | — | — | WO | disclosed |
| WO-1998045354-A1 | SOLUTIONS OF AMINOTRIAZINE RESINS IN MONOALKYLGLYCOLS | BASF AKTIENGESELLSCHAFT (DE) | 1998-10-15 | — | — | WO | disclosed |
| WO-1998045353-A1 | PROCESS FOR PREPARING AMINO RESIN EMULSIONS | BASF AKTIENGESELLSCHAFT (DE) | 1998-10-15 | — | — | WO | disclosed |
| EP-0269079-B1 | METAL-FREE TRANSPARENT, FINELY DIVIDED PHTHALOCYANINE OF THE X MODIFICATION, AND ITS USE AS A PIGMENT | BASF Aktiengesellschaft (DE) | 1993-04-21 | — | — | EP | disclosed |
| EP-0269079-A2 | Metal-free transparent, finely divided phthalocyanine of the X modification, and its use as a pigment | BASF Aktiengesellschaft (DE) | 1988-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220142996-A1 | PHARMACEUTICAL COMBINATION OF AN EP4 ANTAGONIST AND IMMUNE CHECKPOINT INHIBITORS FOR THE TREATMENT OF TUMOURS | PTGER4, EPB41, PTGER1 | CA2 359/4885MAPK1 845/4885CHRM1 3388/4885 |
| US-11590114-B2 | Pharmaceutical combination of an EP4 antagonist and immune checkpoint inhibitors for the treatment of tumours | PTGER4, EPB41, PTGER1 | CA2 359/4885MAPK1 845/4885CHRM1 3388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.